Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

Marco Proietti, Alberto Maria Marra, Eliezer Joseph Tassone, Stefano De Vuono, Salvatore Corrao, Paolo Gobbi, Francesco Perticone, Gino Roberto Corazza, Stefania Basili, Gregory Y H Lip, Francesco Violi, Valeria Raparelli

Research output: Contribution to journalArticle

Abstract

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p

Original languageEnglish
Article number21240
Pages (from-to)877-882
Number of pages6
JournalThe American Journal of Cardiology
Volume116
Issue number6
DOIs
Publication statusPublished - Sep 15 2015

Fingerprint

Left Ventricular Hypertrophy
Atrial Fibrillation
Ankle Brachial Index
Registries
Peripheral Arterial Disease
Population Characteristics
Myocardial Infarction
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Proietti, M., Marra, A. M., Tassone, E. J., De Vuono, S., Corrao, S., Gobbi, P., ... Raparelli, V. (2015). Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. The American Journal of Cardiology, 116(6), 877-882. [21240]. https://doi.org/10.1016/j.amjcard.2015.05.060

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. / Proietti, Marco; Marra, Alberto Maria; Tassone, Eliezer Joseph; De Vuono, Stefano; Corrao, Salvatore; Gobbi, Paolo; Perticone, Francesco; Corazza, Gino Roberto; Basili, Stefania; Lip, Gregory Y H; Violi, Francesco; Raparelli, Valeria.

In: The American Journal of Cardiology, Vol. 116, No. 6, 21240, 15.09.2015, p. 877-882.

Research output: Contribution to journalArticle

Proietti, M, Marra, AM, Tassone, EJ, De Vuono, S, Corrao, S, Gobbi, P, Perticone, F, Corazza, GR, Basili, S, Lip, GYH, Violi, F & Raparelli, V 2015, 'Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation', The American Journal of Cardiology, vol. 116, no. 6, 21240, pp. 877-882. https://doi.org/10.1016/j.amjcard.2015.05.060
Proietti M, Marra AM, Tassone EJ, De Vuono S, Corrao S, Gobbi P et al. Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. The American Journal of Cardiology. 2015 Sep 15;116(6):877-882. 21240. https://doi.org/10.1016/j.amjcard.2015.05.060
Proietti, Marco ; Marra, Alberto Maria ; Tassone, Eliezer Joseph ; De Vuono, Stefano ; Corrao, Salvatore ; Gobbi, Paolo ; Perticone, Francesco ; Corazza, Gino Roberto ; Basili, Stefania ; Lip, Gregory Y H ; Violi, Francesco ; Raparelli, Valeria. / Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. In: The American Journal of Cardiology. 2015 ; Vol. 116, No. 6. pp. 877-882.
@article{b73e29c84fda4c4e8e14d1f5350ef1a9,
title = "Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation",
abstract = "Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the {"}Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study{"} (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56{\%} men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52{\%}) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17{\%}, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93{\%} of LVH and in 73{\%} of patients without LVH (p",
author = "Marco Proietti and Marra, {Alberto Maria} and Tassone, {Eliezer Joseph} and {De Vuono}, Stefano and Salvatore Corrao and Paolo Gobbi and Francesco Perticone and Corazza, {Gino Roberto} and Stefania Basili and Lip, {Gregory Y H} and Francesco Violi and Valeria Raparelli",
year = "2015",
month = "9",
day = "15",
doi = "10.1016/j.amjcard.2015.05.060",
language = "English",
volume = "116",
pages = "877--882",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

AU - Proietti, Marco

AU - Marra, Alberto Maria

AU - Tassone, Eliezer Joseph

AU - De Vuono, Stefano

AU - Corrao, Salvatore

AU - Gobbi, Paolo

AU - Perticone, Francesco

AU - Corazza, Gino Roberto

AU - Basili, Stefania

AU - Lip, Gregory Y H

AU - Violi, Francesco

AU - Raparelli, Valeria

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p

AB - Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p

UR - http://www.scopus.com/inward/record.url?scp=84940523674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940523674&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.05.060

DO - 10.1016/j.amjcard.2015.05.060

M3 - Article

C2 - 26183791

AN - SCOPUS:84940523674

VL - 116

SP - 877

EP - 882

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

M1 - 21240

ER -